Description

Coblopasvir (generic name for ??????) is a first-in-class NS5A inhibitor approved in China under brand name Kailiwei (NMPA H20200001). It is primarily studied in research for chronic Hepatitis?C virus (HCV) infection mechanisms, antiviral activity, drug resistance, and NS5A protein-targeted therapeutics. Each box contains 28 capsules (60?mg × 7 capsules × 4 packs), intended solely for laboratory research use—not for clinical, diagnostic, or veterinary applications.

Product Specifications

Background & Mechanism

• NS5A inhibitor: Coblopasvir specifically targets the HCV NS5A protein, disrupting viral replication and assembly

• First-in-class innovation: Approved February 2020 through NMPA’s priority review procedure as China’s first Category?1 antiviral drug .

Research Applications

• Mechanistic studies of HCV NS5A protein interference

• Preclinical antiviral assays & resistance profiling

• Combination studies with other direct-acting antivirals (e.g., Sofosbuvir)

• Pharmacokinetics and cellular uptake research in hepatocyte models

Safety & Handling

• Administration in humans: Not applicable—strictly for in vitro or animal model research

• Storage: Store sealed below 30?°C in a dry environment

• Handling: Use PPE (lab coat, gloves), avoid ingestion and inhalation

• Waste Disposal: Follow institutional biosafety and hazardous waste protocols

Core Keywords

Coblopasvir capsule, Kailiwei capsule, Coblopasvir hydrochloride, NS5A inhibitor, HCV research capsule, lab-grade antiviral, Beijing Kaiyin antiviral, antiviral research compound, wholesale antiviral research use

Research Use Disclaimer

This product is intended exclusively for laboratory research. It is not approved for clinical, therapeutic, diagnostic, or veterinary use. Misuse may result in safety risks. Please adhere to institutional biosafety guidelines and all applicable laws.